- Active not recruitingPHASE2
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
This study looks at new drug combinations for kidney cancer that has spread or can't be removed. It compares different immune-boosting medicines with a drug called axitinib to see how safe and effective they are.
For: Renal Cell CarcinomaUnited States · Australia · China - Active not recruitingPHASE3
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This study offers continued access to treatments like Avelumab for people who were in earlier Pfizer studies and are still benefiting. It focuses on several cancers and ensures ongoing care and tracking of their health.
For: Advanced Malignancies · NSCLC · Ovarian CancerUnited States · Australia · Belgium - Active not recruitingPHASE1
A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma
This study looks at new drug combinations for advanced kidney cancer. We want to see how safe and effective MEDI5752 is when given with either Lenvatinib or Axitinib to people with this type of cancer.
For: Advanced Renal Cell CarcinomaUnited States · Australia · France